United States: Last Week In 340B: The Revival [Not] Of The 340B Mega-Guidance, Another Senate Hearing, And The Trump Blueprint To Lower Drug Prices

Last Updated: May 23 2018
Article by Ellyn Sternfield

On Wednesday May 9th, I was floored when the Administration released the Spring 2018 Unified Agenda of Regulatory and Deregulatory Actions, which contained this nugget: by December 2018, HRSA will publish its 340B Omnibus Guidance. Readers of our blog know that, as we predicted, this so-called Mega-Guidance was withdrawn in January 2017 without ever seeing the light of day. Within a day, the Unified Agenda was reposted with references to the so-called 340B Mega-Guidance removed, and HRSA acknowledged that its inclusion in the Unified Agenda was an error. The 340B Guidance remains shelved. 

By Friday May 11th we were digesting the Trump Administration's Blueprint to Lower Drug Prices and the significant role 340B plays in the various Blueprint provisions.  Monday brought a speech by the HHS Secretary and his Request for Information (RFI) on the Blueprint, which also highlights 340B. Tuesday May 12th brought a Senate hearing on 340B, and the promise of yet another Senate hearing as additional GAO reports examine 340B operations.

So what does it all mean for 340B?

Senate HELP Committee Hearing

The two witnesses at the Senate hearing were Dr. Debra Draper from GAO and Anne Maxwell from HHS-OIG; both of these individuals testified at the 2015 House hearing on 340B and their testimony repeated familiar themes. Dr. Draper acknowledged HRSA had improved auditing of covered entities, but indicated that 200 audits per year was likely insufficient given the size of the 340B Program. Dr. Draper also stressed that clarity was needed on two points: who was eligible to receive a 340B drug as a patient, and what covered entities were eligible to purchase 340B drugs.

Ms. Maxwell testified about OIG's ongoing concerns about 340B Program integrity, including HRSA's failure to implement a mandated secure pricing system to ensure providers are accurately charged for 340B products, and the failure of Congress to provide legal authority for state Medicaid programs to access 340B prices. Ms. Maxwell also noted that HRSA's delayed regulation of the calculation of manufacturer ceiling prices meant that HHS-OIG had no means to take action if a manufacturer overcharged a covered entity for a 340B drug. Both witnesses stressed the need for congressional action to provide HRSA with broader authority to regulate activity within 340B.

The Senators' questioning of the witnesses illustrated the lack of clear consensus over the purpose of the 340B Program, including whether covered entities should be required to provide 340B drugs to patients at or below the discounted 340B prices. Several Senators bemoaned HRSA's shelving of the 340B Mega-Guidance, despite the witnesses' testimony that legislation was necessary for the Guidance to be effective. Senator Elizabeth Warren took another tact, honing in on the Administration's continued delayed implementation of the HRSA rule on ceiling prices. Senator Warren ironically juxtaposed the rhetoric in the Administration's Blueprint attacking high drug prices, with the Administration's continued unwillingness to enforce a regulation that attempts to control manufacturer overcharging in the 340B Program.

HRSA did not appear at the hearing, but the Chairman stated there would be a later Senate hearing involving HRSA testimony. Dr. Draper also stated that the GAO is not done with its focus on 340B. This summer, GAO anticipates publishing two reports on 340B. The first report will be specific to 340B contract pharmacies, and will examine financial arrangements; the second will be specific to 340B hospitals, and will compare the characteristics of 340B hospitals to non-340B hospitals.

Trump Administration Blueprint on Drug Prices

The basic question surrounding the Administration's Blueprint to lower drug prices is whether the Administration is long on rhetoric but short on substantive action. Specific to 340B, the administration sees "further opportunities" for 340B reform, but outside of touting the Medicare Part B reimbursement cut that went into effect in January 2018, no specific "opportunities" were mentioned. Instead, the Blueprint raises a myriad of questions to which it seeks input, such as whether growth in the 340B program has been cross-subsidized by price increases in the private sector.  Interestingly, the Administration asks whether expanding regulations or changing the qualifications of the entities/patients eligible for 340B would "help refocus the program towards its intended purpose," without ever defining that purpose.

Secretary Azar's comments on Monday were more pointed, largely targeting manufacturers and pharmacy benefit managers. He went into more detail with the RFI, referencing the President's 2019 Budget that proposes 340B reforms "to ensure that the benefits derived from participation in the program are used to benefit patients, especially low-income and uninsured."  However, like the budget document itself, the RFI provides no details on those reforms. Instead, the RFI doubles down on future input, seeking comments on a broad range of topics affecting 340B, including cross-subsidization, potential eligibility requirements, and how to prevent duplicate discounts.

What Comes Next? 

There will be at least one more Senate hearing on 340B. But what about actual legislative action?  My personal view is that when it comes to 340B, there does not exist the necessary consensus to get a bill out of both houses of Congress and onto the President's desk.

What does that mean for the future of 340B?  Given the Administration Blueprint and RFI claiming the Medicare Part B reimbursement cut for 340B drugs as a "victory" against high drug prices, I still see Medicare reimbursement as the vehicle for future attempts at 340B reform. I also believe that we will not see any specifics on that vehicle until there is a decision from the Court of Appeals on the pending legal challenge to CMS' reimbursement cut.

Moreover, in the days following the publication of the RFI, Secretary Azar's rhetoric has become more inflammatory. On Tuesday May 15th, CMS published enhanced data on drug pricing, accompanied by a chart highlighting double digit increases in the prices of a number of commonly used drugs since 2012. The Secretary has also publicly ruminated on the possibility of folding Medicare Part B into Part D, and giving plans broader authority to negotiate discounts in the combined programs.

So what will happen next? The real answer is that as of yet, there are more questions than answers.  So stay tuned.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Ellyn Sternfield
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions